News

Minneapolis – Preventice Solutions announced today the appointment of Tom Sheehy as executive vice president (EVP) and chief commercial officer (CCO). In this role, Sheehy will lead the Preventice commercial organization, including sales, marketing and product management.

Sheehy joins Preventice from Medtronic, where he recently served as a senior area sales director for the Diagnostics and Coronary sales team.

"We are excited to welcome Tom to Preventice," said Jon Otterstatter, Preventice chief executive officer. "He is deeply respected within the industry and brings valuable expertise and insights that will complement the strengths of our leadership team. I look forward to his contributions to the company, including his thoughtfulness and trustworthy passion, as well as the new perspective he will bring to our commercial organization."

Over the past seven years, Tom has held several leadership roles at Medtronic, including a national sales leadership role integrating TYRX antibiotic envelopes with the pacemaker sales team and three years as the vice president of AF sales for their cryoablation technology. Under his leadership, his past teams have accomplished sales growth of more than 20 percent in both of those businesses. For the twenty years prior to his time at Medtronic, Tom worked in various sales management roles for both St. Jude Medical (now Abbott) and Guidant (now Boston Scientific).

"I see in Preventice the opportunity to continue to create significant shareholder value, and I couldn't be more excited to join the leadership team in remote cardiac monitoring and contribute to its Mission," said Sheehy. " I have full confidence in the strategy, and our ability to unlock that value in the months and years ahead."

Sheehy assumes his position at Preventice effective January 6th, 2020 and will report to Jon Otterstatter.

About Preventice Solutions

Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian ® family of monitors. For more information please visit www.preventicesolutions.com.

PDF Print

Minneapolis – Preventice Solutions announced today it received a tender from the UK Biobank to provide the BodyGuardian® MINI remote cardiac monitor for a cardiovascular monitoring study involving up to 30,000 participants. The study is designed to capture data on asymptomatic heart rhythm disturbances (arrhythmia), including atrial fibrillation (AF), a common arrhythmia that can lead to stroke and cognitive decline (dementia).

Not only will the study capture real-life heart rhythm information, but it is being undertaken on UK Biobank volunteers who have undergone heart and brain MRI as part of the biggest imaging study ever done.

The study has been funded by the British Heart Foundation (BHF) and is led by Professor Barbara Casadei, who is BHF Professor of Cardiovascular Medicine, at the Cardiovascular Medicine Division of the Radcliffe Department of Medicine, University of Oxford.

Professor Casadei said: “Atrial fibrillation is a common condition that can go unnoticed until it causes a stroke or cognitive decline. We desperately need to know more about its causes and how it can be better treated.”

“UK Biobank provides us with an ideal opportunity to integrate a large amount of health, genetics and lifestyle information with heart rhythm data on a huge number of people. Importantly these individuals will have also undergone an MRI heart, body and brain scan. It is not often that all these opportunities for discovery come together – because of this, we believe this study will provide important answers about the management and risk associated with asymptomatic AF and other clinically silent arrhythmias.”

Preventice Solutions Chief Executive Officer Jon Otterstatter, said: “The BodyGuardian® MINI was designed to enhance compliance through ease-of-use and comfort based on its small size and waterproof design allowing participants to go about their daily activities without interruption. We look forward to helping researchers pursue this important research and are pleased to partner with the UK Biobank, British Heart Foundation and the Radcliffe Department of Medicine at Oxford as they collaborate on important research efforts to further understand AF and its impact on stroke and cognitive decline.”

This study is part of the UK Biobank Imaging Project, which is almost halfway to its goal of collecting detailed brain, heart and body scans of 100,000 of its volunteer participants. The BodyGuardian® MINI remote cardiac monitor will be used to obtain longer term heart rhythm data on a subset of participants 65 years of age and older. The project is anticipated to last around three years.

The BodyGuardian® MINI is the smallest, reusable Holter monitor available. It records important physiological data such as heart rate, ECG and related activity, allowing physicians to monitor vital signs outside the clinical setting. Unlike many other remote monitors, the MINI device offers a wearable patch that can be moved and reapplied to optimize comfort and wearability, without jeopardizing data collection or requiring the participant to return to the clinic. In addition, it is fully waterproof, allowing participants the freedom to go about their daily life without interrupting cardiac monitoring.

UK Biobank is a major national and international health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

The British Heart Foundation funds over £100 million of research each year into all heart and circulatory diseases and the things that cause them. Their vision is a world free from the fear of heart and circulatory diseases. The Foundation raises money to research cures and treatments to beat heartbreak forever.

The Radcliffe Department of Medicine at Oxford was formed in 2012 and is a multi-disciplinary department with research interests that span the translational spectrum – from basic biology through to clinical application. The department’s ultimate aim is patient benefit, through improved understanding, diagnosis and treatment of disease.

About Preventice Solutions

Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian® family of monitors. For more information please visit www.preventicesolutions.com.

PDF Print

Duration of External ECG Monitoring is Critical to Detecting Atrial Fibrillation

Data show greater than 10 percent of patients with atrial fibrillation are missed if monitoring is stopped at 14 days versus monitoring for at least 28 days

Minneapolis - May 9, 2019 – Preventice Solutions announced today the presentation of data showing the critical impact the length of the monitoring period has when using ambulatory remote ECG monitoring to detect atrial fibrillation (AF). While the Preventice BodyGuardian® Remote Monitoring System has the capability and reimbursement to support patient monitoring for up to one month, it is common practice with many currently available monitoring technologies to limit the monitoring period to one to two weeks. This truncated duration of monitoring is associated with “missed” AF in more than 10 percent of patients, many of whom have greater than one hour of AF. The data was presented Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions by Suneet Mittal, MD, FHRS from The Valley Hospital and Pooja Mehta and Michael McRoberts from the Preventice data science team.

“In the case of AF, data on the appropriate use of monitoring technologies, including the prescription of a sufficient monitoring period out to a full 28-days, is an important consideration,” said Dr. Suneet Mittal, MD, Associate Chair of Cardiovascular Services for Valley Medical Group, Medical Director of The Valley Hospital’s Snyder Center for Comprehensive Atrial Fibrillation, and Director of Cardiac Research for Valley Health System. “Medicine is moving away from the transactional approach, which involves the doctor only thinking about the patient when the patient is in the clinic. Remote monitoring is changing that paradigm because there is physiologic data that can be captured between visits and used to inform clinical decisions that will optimize care. With AF, there are different patient populations. It is critical to ensure the monitoring technology is fully leveraged to make an appropriate diagnosis and gauge the burden on the patient, which informs our treatment approach.”

The study was a retrospective analysis designed to compare the incremental yield of AF detection when ambulatory remote ECG monitoring is extended from 14 to 28 days. In the study, data was evaluated from 25,457 randomly selected patients who had undergone monitoring with the BodyGuardian® Remote Monitoring System. The results show at least one AF episode was present for 4,033 patients (15.8 percent) during the 28-day monitoring period. Of those who had AF, 424 patients (10.5 percent) would have been missed if the monitoring period had been truncated at 14 days. From those 424 patients, 352 (or 8.7 percent of the 4,033 patients with AF) had AF for greater than 1 hour, and 181 (or 4.5 percent of the 4,033 patients with AF) had AF for greater than 6 hours.

“We have developed the BodyGuardian® Remote Monitoring System to address the critical needs of patients and physicians. We continue to understand, advance and validate the system based on clinical data,” said Jon Otterstatter, Chief Executive Officer, Preventice Solutions. “Influencing a positive effect on outcomes requires that our technology is proven by clinical evaluation and common practice. Our technology was created with the full capability to monitor accurately and effectively for up to one month of data capture. This study shows the importance of leveraging full capabilities of the technology that can lead to complete actionable data and achieve the best outcomes for patients.”

Dr. Mittal has received no compensation from Preventice for his involvement in this project.

About the BodyGuardian® Remote Monitoring System

BodyGuardian Heart is a small, lightweight, wireless monitor in the BodyGuardian family of monitors. It records important physiological data such as heart rate, ECG, respiratory rate and related activity. Through Bluetooth®, the smartphone can also capture additional physiological measurements such as blood-oxygen, glucose levels, blood pressure and weight, anytime, anywhere. The system creates a virtual connection between patients and their care teams, allowing physicians to monitor vital signs outside the clinical setting.

The BodyGuardian® Remote Monitoring System includes integration of the BodyGuardian family of monitors and additional third-party sensors, the BodyGuardian Connect smartphone patient application and the PatientCare Platform. The system utilizes machine learning to remotely recognize AF and integrate data into the electronic health record. Patients wear cardiac monitors, which feed real-time data into the cloud-based health platform that physicians can access. Growing clinical use resulting from increased incidence of cardiac disease and a rising aging population forces a greater reliance on algorithms in order to provide high-quality reporting in a timely manner. These factors are amplified in the case of mobile cardiac telemetry (MCT), where ECG is streamed directly to data processing centers, annotated, and may be used to quickly alert clinicians of potentially critical cardiac events.

About Preventice Solutions

Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias with their care team. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian family of monitors. For more information please visit www.preventicesolutions.com.

PDF Print

Minneapolis - May 8, 2019 – At Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions, Preventice Solutions will present clinical data validating its BodyGuardian® Remote Monitoring System with the BeatLogic™ deep learning platform. This technology leverages machine learning and artificial intelligence (AI) for detection of atrial fibrillation (AF) and was validated using clinician adjudicated data. The BodyGuardian® Remote Monitoring System is designed to create a constant connection to monitor cardiovascular data in patients outside the clinic while they go about their daily activities. The data was presented by Hamid Ghanbari, MD, MPH, FACC from University of Michigan in Ann Arbor and Ben Teplitzky, PhD, and Mike McRoberts, from the Preventice data science team.

“One of the exciting advances in the diagnosis of AF is the use of machine learning techniques and deep learning technology because it can allow physicians to manage the massive amount of data that is collected,” said Dr. Hamid Ghanbari, MD, MPH, a cardiovascular electrophysiologist at the University of Michigan, where he treats patients who have arrhythmias. “Sensor technologies are creating so much data it’s not feasible for physicians to be able to manage and review all of it. With accurate artificial intelligence to identify AF episodes, physicians can focus more on how their patients are feeling and the treatment approach they should take in each case. Artificial intelligence is freeing up the human potential with remote monitoring technologies.”

Results from the study demonstrate how the BeatLogic™ deep learning platform is used to accurately detect the beginning and end of arrhythmias ensuring accurate burden calculations and maximizing clinical value. The platform leverages multiple deep neural networks to detect AF episodes at rates that meet or exceed the best reported values within the literature. Perfect detection performance was achieved for AF episodes lasting more than one minute.

The study evaluated the AF detection performance of the Preventice BeatLogic™ platform using real-world clinician adjudicated data. The BeatLogic™ platform consists of multiple deep neural networks, which were trained using data from 10,946 BodyGuardian® Heart patients. Performance was measured using real-world BodyGuardian® Heart data from 512 patients that was annotated and then adjudicated by three board certified electrophysiologists. Specific results showed:

• AF duration sensitivity (Se) and a positive predictive value (PPV) were 95.9 percent and 99.2 percent, respectively

• Episode detection Se and PPV were 96.7 percent

• Episode detection Se and PPV increased to 100 percent for AF episodes with duration >1 minute.

Wearable patch ECG monitoring quantifies AF burden using a combination of algorithms and trained technicians. New deep learning algorithms have improved the performance with respect to accurately detecting the presence of AF using algorithms. By leveraging multiple deep learning networks, the Preventice system is capable of accurately capturing the beginning and end of AF episodes, providing physicians with important clinical context for determining the appropriate treatment approach.

“Our focus in advancing Preventice remote monitoring technologies is on how to make these technologies most meaningful to the physician and the patient,” said Jon Otterstatter, Chief Executive Officer, Preventice Solutions. “Given the large amount of data available through remote monitoring, we’re investing heavily in machine learning, designing and validating algorithms. The precise detection of cardiovascular events, like AF, is critical to reaching an accurate diagnosis and treatment.”

Dr. Ghanbari has received consultation fees from Preventice for advising on remote monitoring technology and services.

About the BodyGuardian® Remote Monitoring System

BodyGuardian Heart is a small, lightweight, wireless monitor in the BodyGuardian family of monitors. It records important physiological data such as heart rate, ECG, respiratory rate and related activity. Through Bluetooth®, the smartphone can also capture additional physiological measurements such as blood-oxygen, glucose levels, blood pressure and weight, anytime, anywhere. The system creates a virtual connection between patients and their care teams, allowing physicians to monitor vital signs outside the clinical setting.

The BodyGuardian® Remote Monitoring System includes integration of the BodyGuardian family of monitors and additional third-party sensors, the BodyGuardian Connect smartphone patient application and the PatientCare Platform. The system utilizes machine learning to remotely recognize AF and integrate data into the electronic health record. Patients wear cardiac monitors, which feed real-time data into the cloud-based health platform that physicians can access. Growing clinical use resulting from increased incidence of cardiac disease and a rising aging population forces a greater reliance on algorithms in order to provide high-quality reporting in a timely manner. These factors are amplified in the case of mobile cardiac telemetry (MCT), where ECG is streamed directly to data processing centers, annotated, and may be used to quickly alert clinicians of potentially critical cardiac events.

About Preventice Solutions

Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias with their care teams. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian family of monitors. For more information please visit www.preventicesolutions.com

PDF Print

Alliance breaks down silos of information, putting a single source of triaged data into the hands of clinicians
Orlando – GE Healthcare (NYSE:GE) is working with Preventice Solutions to give clinician tools to follow patients with known or suspected Atrial fibrillation virtually from hospital to home. Atrial fibrillation, or AF, is an irregular and often rapid heart rate that can increase risk of stroke, heart failure and other heart-related complications, and, as the population ages globally, AF is predicted to affect 6 to 12 million people in the United States alone by 2050.

The collaboration offers a single vendor solution that is integrated with MUSE for seamless order-to-reporting workflow. According to U.S. News & World Reports, 24 out of 25 top U.S. cardiac hospitals use MUSE1. By integrating with MUSE, data from home-based patients will be made available to clinicians on the same clinical workspace they use every day.

“This development in our relationship with Preventice creates an integrated, longitudinal view of the patient experience,” said GE Healthcare Diagnostic Cardiology General Manager Ashutosh Banerjee. “We’re enabling the ECG record to grow with a richness that will allow the clinician to see how her treatment is working for the patient at home.”

“This partnership is transforming connected care in the industry with our customers benefiting from a consistent patient experience with enhanced clinical insight,” said Preventice Solutions Chief Executive Officer Jon Otterstatter. “This alliance will help standardize the operations and workflow for healthcare providers resulting in improved quality.”

GE Healthcare and Preventice Solutions are announcing this latest progression of their strategic relationship at HIMSS 2019, February 12 - 15, 2019 in Orlando.

About GE Healthcare
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE).  As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services.  With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world.  Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website www.gehealthcare.com for more information. 

About Preventice Solutions
Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian family. For more information please visit www.preventicesolutions.com.

1 “Best Hospitals for Adult Cardiology & Heart Surgery." US News. U.S. News & World Report, n.d. Web. 14 Aug. 2015. https://health.usnews.com/best-hospitals/rankings/cardiology-and-heart-surgery Based on internal sales data to the listed facilities. 

PDF Print

Minneapolis – At Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions in Boston, May 9-12, 2018, Preventice Solutions will showcase practical applications of machine learning and artificial intelligence (AI) in wearable cardiac monitoring technology. Clinical data will be presented in a poster validating the proprietary algorithms that are part of the BodyGuardian® Heart system, which is designed to create a constant connection between patients and their healthcare team. The poster is authored by Ben Teplitzky, PhD, and Mike McRoberts, from the Preventice data science team, and Suneet Mittal, MD, FHRS, from Valley Medical Group.

Preventice Solutions is presenting real-world validation of the unique algorithms used in the BodyGuardian® Heart system to detect ventricular ectopic beats (VEBs), which are a sub-category of abnormal heart contractions that originate from the ventricles. For some patients, these beats signify a potential life-threatening and treatable cardiac irregularity. The proprietary algorithm, when used with mobile cardiac telemetry technology, empowers physicians and healthcare providers with valuable information regarding the occurrence and regularity of VEBs.

In the study, algorithm validation was performed using the MIT-BIH arrhythmia database and also using real- world data collected from nearly 2,000 BodyGuardian® Heart patients. Results demonstrate that this proprietary classification model has sensitivity and specificity higher than any previously published fully automated algorithms and demonstrates key short-comings associated with validation performed using only the MIT-BIH arrhythmia database.

“In my opinion, clinicians do not always appreciate the difficulty that ambulatory ECG monitoring systems have in accurately differentiating VEBs from normal sinus rhythm,” said Dr. Mittal. “The application of deep learning to large real-world ECG datasets provides a unique opportunity to enhance the diagnostic accuracy of the algorithms in these ECG monitoring devices.”

Dr. Mittal has received no compensation from Preventice for his involvement in this project.

PDF Print

Next big advance in cardiac monitoring delivers up to 14-days of ECG measurements Compact and easy-to-use technology designed for patient compliance and physician satisfaction.

Minneapolis – Preventice Solutions announced today the launch of the BodyGuardian® MINI, the smallest, reusable long-term Holter technology available for cardiac monitoring. The new, compactly designed technology includes an ultra-small, lightweight cardiac monitor that enables up to 14-days of ECG measurements that are transmitted to a physician in an easy-to-read, data-rich report. Preventice Solutions announced the launch of the BodyGuardian® MINI in conjunction with the kick-off of Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

“Our vision for the BodyGuardian® Heart system has been grounded in transformative advancement of the technology to address patient and physician needs,” said Jon Otterstatter, Chief Executive Officer, Preventice Solutions. “Innovative thinking is built into every BodyGuardian® MINI. It is an example of technology progress that directly enhances patient compliance through ease-of-use and comfort based on its small size and reusable, waterproof design. For physicians, the MINI is a technological innovation that can achieve up to 14-days of ECG measurements with fast access to an easy-to-read, data-rich report.”

The BodyGuardian® MINI is the smallest, reusable long-term Holter monitor available. Unlike many other long-term Holters, the new MINI device offers a wearable patch that can be moved and reapplied by the patient to optimize comfort and wearability. It can also be replaced during the study without jeopardizing data collection or requiring the patient to return to the clinic. In addition, it is waterproof, allowing patients the freedom to go about their daily routine without interrupting cardiac monitoring. Due to its small size, and its ability to be placed centrally on the chest, BodyGuardian® MINI can optimally and proportionally capture the P-wave.

“Remote cardiac monitoring is an important technology used in the diagnosis of cardiac rhythm abnormalities,” said Ziad F. Issa, MD, Executive Director, Cardiac Electrophysiology, Prairie Heart Institute of Illinois. “Recent advances in technology will make these systems easier for patients to use and even more specific in helping physicians gather insights needed to make accurate clinical diagnosis with faster access to the specific, detailed data from patients, while they go about their daily activities.”

PDF Print

New partnership provides seamless connection between leading provider of hospital ECG products, including MUSE, and leader of ambulatory ECG services.

Boston – GE Healthcare (NYSE:GE) is working with Preventice Solutions to provide customers with an extension of the hospital heart station and to expand GE Healthcare ECG services into the home, creating a more holistic solution for monitoring ambulatory ECG patients.

The partnership offers a unified solution to providing in-hospital ECG, long-term Holter, Cardiac Event Monitoring (CEM) & Mobile Cardiac Telemetry (MCT) results into a single portal utilizing the GE Healthcare MUSE cardiac management system.

According to U.S. News & World Report, 23 out of 25 top U.S. cardiac hospitals use MUSE. By integrating with MUSE, data from home-based patients will be made available to clinicians on the same clinical workspace they use every day.

“GE Healthcare is working with Preventice Solutions to drive both better clinical outcomes for patients and greater financial results for customers,” said GE Healthcare Diagnostic Cardiology General Manager Ashutosh Banerjee. “Our partnership holds the power to create a consistent patient experience and a high standard of clinical care, providing hospital-quality ECG algorithms to ECGs acquired outside the hospital. This alliance will help standardize operations management and workflow for health care providers.”

"We are excited to partner with GE Healthcare and to join forces on additional areas of mutual strategic interest,” said Preventice Solutions Chief Executive Officer Jon Otterstatter. “Our collaboration will create an integrated, longitudinal view of the patient experience and a unique ability to empower clinicians with timely, data-driven decisions in an actionable, seamless way.”

GE Healthcare and Preventice Solutions are announcing their strategic partnership at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, May 9-12, 2018 in Boston.

About GE Healthcare
Harnessing data and analytics across hardware, software and biotech, GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging equipment, with a track record of more than 100 years in the industry and more than 50,000 employees across 100 countries, we transform healthcare by delivering better outcomes for providers and patients. Follow us on Facebook, LinkedIn, and Twitter or The Pulse for latest news.

About Preventice Solutions
Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. The Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian family. For more information please visit www.preventicesolutions.com.

“Best Hospitals for Adult Cardiology & Heart Surgery." US News. U.S. News & World Report, n.d. Web. 14 Aug. 2015. http://health.usnews.com/best-hospitals/rankings/cardiology-andheart-surgery

PDF Print

Minneapolis – Preventice Solutions announced today it received the 2017 Frost & Sullivan Product Line Strategy Leadership Award for its remote cardiac monitoring portfolio of technologies and services. Following an analysis of the remote cardiac monitoring industry in North America, Frost & Sullivan selected Preventice for the award based on the company’s commitment to leveraging product strategies to enhance customer value and experience, going beyond short-term impact on revenues.

In the time of performance based reimbursement, Preventice offers innovative remote monitoring technologies and services that support the diagnosis of cardiac arrhythmias and create a seamless connection between patients and providers. The company’s portfolio includes wearable monitors, such as the BodyGuardian® Heart, and diagnostic monitoring services, including data transmission, surveillance, reporting, interpretation and integration into a physician’s workflow via interoperability with electronic medical record (EMR) platforms.

"Preventice is an emerging industry leader for cardiac remote patient monitoring that provides a comprehensive solution for physicians and patients alike," said Patrick Riley, MBA, MHA, CHE, Frost & Sullivan Principal Analyst. "Preventice Solutions offers its own Independent Diagnostic and Testing Facility that provides physicians 24/7 access to patient arrhythmia data. Using Preventice's BodyGuardian® Remote Monitoring System helps physicians see into their patients’ experience — the what and when — which helps them refine their care."

For the Product Line Strategy Leadership Award, Frost & Sullivan analysts independently evaluated Product Line Strength (breadth, scalability, technology leverage, etc.) and Customer Impact (price/performance value, customer experience, etc.).

“We are proud to receive this recognition from Frost & Sullivan for our commitment to addressing customer value and experience with our advanced technologies and services for remote cardiac monitoring,” said Jon Otterstatter, Chief Executive Officer, Preventice. “Our focus from the beginning has been on understanding and addressing physician and patient needs with a comprehensive portfolio of monitoring technologies and services. For physicians, it means access to data on how their patients are doing, and for patients, it’s technology that allows them to go about their daily activities without restrictions.”

Preventice designed a customizable and configurable platform to enable arrhythmia monitoring. The architecture readily extends to allow remote monitoring using different types of devices. The scalability, security, and extensibility requirements imbedded in the design create the foundation of a chronic care platform that can be used for a range of clinical solutions.

Preventice started as a software company focused on developing practical solutions by actively listening to clinician and patient problems that need to be solved quickly. The Preventice development team responded with a powerful system designed to deliver clinical data in near real-time to clinicians, while making it easy for patients to use the monitor at home, work or throughout their daily activities. Patient mobility, ease of use and simplicity were keys to an effective solution.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About BodyGuardian® Heart
BodyGuardian® Heart is a small lightweight wireless monitor that records important physiological data such as heart rhythm, ECG, respiratory rate and related activity. Through Bluetooth®, and other approved technology, the smartphone can also capture additional physiological measurements such as blood-oxygen, glucose levels, blood pressure and weight, anytime anywhere. The system creates a virtual connection between patients and their care teams, allowing physicians to monitor vital signs outside the clinical setting, while patients go about their daily lives.

The data is captured by BodyGuardian® Heart in near real-time, and the programmatic triage, created based upon the physician’s care protocol, can improve care delivery and lower costs. The Preventice monitoring center team analyzes, summarizes, and can ultimately empower clinicians to timely data-driven clinical decisions using an integrated EMR data management system.

About Preventice Solutions
Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias. Using insights to create revolutionary monitoring technologies, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes. Preventice wearable portfolio includes the PatientCare Platform and BodyGuardian® family. For more information please visit www.preventicesolutions.com

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

PDF Print

Houston and Rochester – Preventice Solutions, a leading developer of mobile health solutions and services, today announced the launch of its new website, www.preventicesolutions.com.

The new Preventice Solutions site offers an attractive design, easy-to-navigate functionality, and a content-rich site experience. It focuses upon increasing education and engagement with patients and health care professionals. Moreover, the new website will continue to showcase the superior quality of Preventice Services and the innovation of Preventice Technologies as we develop and deploy new remote monitoring solutions for patients burdened by cardiac-related issues and associated health disorders.

Key elements of the redesigned website include: enhanced product pages and resources providing quick access to information, improved content, and advanced search capabilities, a new feedback function makes it easier for users to share their experience, optimization for iPad and mobile devices, easy access to PatientView, PatientFlow, and PatientCare portals.

“This change to our company website reflects our broader health care commitment in driving remote monitoring technologies and services needed to improve patients’ well- being,” said Jon Otterstatter, President and Chief Global Strategy Officer, co-CEO, Preventice Solutions. “The new design has been crafted to reflect what patients and customers told us they require now, while building for future needs, a transformative patient- centric approach benefiting from the capabilities of Preventice Services and Preventice Technologies.”

“We understand that no two health care organizations are exactly alike. Our new website was created with these differences in mind. Connecting with new or existing patients often requires a creative multi-channel approach. Through our listening pipelines led by our national salesforce, we can support health care practices centered on the highest quality ofpatient care,” said John Untereker, co-CEO, Preventice Solutions.

PDF Print

Houston and Rochester – Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related diagnostic and monitoring offerings.

"This agreement marks an important strategic milestone for Preventice Solutions," said Jon Otterstatter, President and Chief Global Strategy Officer, co-CEO, Preventice Solutions.  "We are thrilled to partner with Boston Scientific and collaborate on additional areas of mutual commercial and strategic interest. By partnering with Boston Scientific, we will expand our service capability and build a foundation for a future in the management of remote patient care," said John Untereker, Executive Vice President and Chief Operating Officer, co-CEO, Preventice Solutions. 

The market for cardiac monitoring solutions is greater than $1B. Technologies include wearable monitors that detect and record heart rhythms such as Holter, cardiac event monitors (CEM), mobile cardiac telemetry (MCT) as well as implantable or insertable cardiac monitors. These products are often surrounded by monitoring services including data transmission, surveillance, reporting, interpretation, and integration into a provider's workflow. Preventice Solutions' portfolio includes PatientCare Platform and the BodyGuardian® range of products i.e. BodyGuardian® Heart, BodyGuardian® Verité and BodyGuardian® Holter.

About Preventice Solutions

Preventice Solutions, a leading developer of mobile health solutions and services, was created by a strategic combination of Preventice Services, formerly eCardio Diagnostics® and Preventice Technologies, formerly Preventice® in 2014.Together, we are designing the industry's superior customer service experience. Using insights to create revolutionary monitoring technologies and services that connect patients and caregivers, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes.  To learn more about Preventice Solutions, visit www.preventicesolutions.com

PDF Print

Houston and Rochester – Preventice Solutions announced today that BodyGuardian® Heart Remote Patient Monitoring System and PatientCare platform will be commercially available in Q3, 2015. Testing with the BodyGuardian® Remote Monitoring System is underway nationally to ensure ongoing improvements and care team efficiency. It will target the use of remote monitoring including:
• Post-surgical cardiac patients to evaluate how monitoring cardiac rhythms remotely influence all phases of recovery.
• 24/7 continuous monitoring of infrequently symptomatic patients as they go about their daily lives, with the objective of detecting potential arrhythmias by tracking ECG, respiratory rate and activity.

Preventice Solutions will demonstrate the BodyGuardian® Heart and the PatientCare Platform at the HRS 2015 http://www.mhealthsummit.org/, one of the industry's leading conferences in research, delivery of arrhythmia care and services, in Boston, MA, May 13-16, 2015.  The BodyGuardian® uses sophisticated algorithms to support remote monitoring for individuals with cardiac arrhythmias.

John Untereker, Executive Vice President and Chief Operating Officer, said "Innovative remote monitoring technology will help physicians gain deeper insights into their patients' health by collecting near real-time data.  BodyGuardian® Heart will allow healthcare practitioners to monitor critical measures and manage many patients, thus safeguarding the health and safety of individuals every day.  This approach will ultimately transform how health care is delivered for many common cardiac and chronic diseases."

"We are close to achieving two important milestones for the BodyGuardian with the commercial availability in early summer and robust piloting here in the United States.  The beta testing is a direct indicator of significant interest in BodyGuardian® by early adopters and proves their belief that Preventice Solutions is poised to change the future of remote monitoring," said Jon Otterstatter, President and Chief Global Strategy Officer of Preventice Inc.

"We are excited to partner with Preventice Solutions and pleased to see BodyGuardian® takes another step in its success story. This collaboration represents a great opportunity to provide our patients with remote monitoring," said Dr. Craig J. McCotter, MD, Upstate Cardiology Greenville, South Carolina. "The combination of the BodyGuardian® Heart and the PatientCare Platform allows us to achieve superior monitoring and support our patients at home, as if they were at the clinic."

About BodyGuardian® Heart 
Preventice® received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2012.  The BodyGuardian® System detects records and wirelessly transmits physiological data to support remote monitoring of non-lethal, cardiac arrhythmias in ambulatory patients. Data is transmitted to the Monitoring Center platform, where it can be stored for up to 30 days at a time. Medical professionals can securely view the captured medical information. Physicians can retrieve patient data and reports, or choose to receive alerts based on changes in select biometrics. The BodyGuardian Heart is small sensor that adheres to the patient's skin giving patients freedom to go about their normal lives without restriction.

About Preventice Solutions
Preventice Solutions is a strategic combination of eCardio Diagnostics and Preventice. Together, we are designing the industry's super customer service experience. Using patient and physician insights to create revolutionary monitoring technologies and services that connect patients and caregivers in a way that redefines what healthcare can be. Operating and corporate functions will be managed from eCardio's existing corporate headquarters in Houston while the clinical research and product development activities will remain at Preventice's Rochester, Minn., location. eCardio's two Independent Diagnostic Testing Facilities will continue to monitor patients from Houston and South San Francisco. 

PDF Print

San Francisco – AliveCor, Inc. announced today the launch of a cloud based electrocardiogram (ECG) analytics program with Preventice Solutions, a strategic combination of eCardio Diagnostics and Preventice, a leading provider of remote monitoring products and services.

Using AliveCor’s proprietary algorithms in this pilot program, Preventice Solutions intends to improve its internal workflow by reading the most critical ECGs first. This is a limited pilot program where all ECGs have their final interpretation provided by the award winning independent diagnostic testing facility of eCardio, which is owned by Preventice Solutions; it is the beginning of a new platform for AliveCor’s proprietary algorithms.

AliveCor is known for its AliveCor® Heart Monitor – a mobile ECG device– and its mobile app for consumers called AliveECG. For the first time, the company is evaluating the use of their FDA-cleared algorithms for patients being monitored using an AliveCor device as well as a traditional cardiac event monitor. This potential expansion of AliveCor’s services may extend its automated ECG analytics to cardiac monitoring companies like Preventice Solutions and hospital cardiology departments providing an easy to use, physician-led way of monitoring patients for suspected or diagnosed arrhythmias.

“The intention of this new pilot program is to demonstrate the power of our algorithms and is just the start of a larger ECG based analytics program that we are working to develop and obtain clearance for. We believe that our ECGs and algorithms can provide guidance to medical practitioners and patients and as a result help to make better, more informed decisions,” said Euan Thomson, President and Chief Executive Officer at AliveCor. “Not only can hospitals use our algorithms for screening programs and day-to-day monitoring, we will be able to extend the access of our algorithms to a variety of companies that may have a need to analyze ECGs from traditional or mobile event monitors.”

“We are coming together at a pivotal time in the mobile healthcare industry. As health reform demands more focus on delivering quality outcomes and reducing costs, providers are turning to technology like remote monitoring to diagnose and treat more patients in ways that use time, money and human resources efficiently and effectively. Our shared vision is to become a worldwide leading remote monitoring company” said Jon Otterstatter, President and Chief Global Strategy Officer of Preventice Inc.

This strategic program expands upon AliveCor and Preventice Solutions’ current relationship. Through the AliveECG app, AliveCor users are provided with an analysis service that offers expert review of ECGs, powered by eCardio independent monitoring diagnostic facility owned by Preventice Solutions. Users can send ECG readings to remote cardiac technicians for detailed interpretation, at any time, providing users with a more complete picture of their current heart health. Patients can either pay $2 to get their report back in 24 hours, or $5 to get their report within 30 minutes.

About AliveCor, Inc.
AliveCor Inc. is a global innovator in mobile technology for heart health. AliveCor works with health systems to help identify patients with undiagnosed heart conditions before potentially life-threatening conditions, like stroke, can occur. AliveCor helps diagnosed patients work with their physician to monitor, track and manage their condition in new ways. AliveCor is a privately-held company headquartered in San Francisco, Calif. For more information, please visit www.alivecor.com. AliveCor is a trademark of AliveCor, Inc., registered in the U.S. and other countries.

About Preventice Solutions 
Preventice Solutions is a strategic combination of eCardio and Preventice. Together, we are designing the industry’s most “tuned in” customer service experience. Using patient and physician insights to create revolutionary monitoring technologies and services that connect patients and caregivers in a way that redefines what healthcare can be.

Operating and corporate functions will be managed from eCardio’s existing corporate headquarters in Houston while the clinical research and product development activities will remain at Preventice’s Rochester, Minn., location. eCardio’s two Independent Diagnostic Testing Facilities will continue to monitor patients from Houston and South San Francisco. eCardio Diagnostics, LLC and Boost Information Systems, Inc., doing business as Preventice, are independent, wholly owned subsidiaries of Preventice, Inc.

About eCardio Diagnostics, LLC
eCardio Diagnostics is a leading partner in the delivery of optimal patient care by offering the complete wireless monitoring solution for physicians needing accurate and timely arrhythmia detection in the outpatient setting. Winner of numerous awards from the technology, health, and business sectors, eCardio provides a vast array of products including mobile cardiac telemetry (MCT) and cardiac event monitors. Our leading-edge diagnostic innovations and digital solutions, combined with our award-winning Monitoring Centers provide physicians and their patients with flexible, fast, and accurate arrhythmia monitoring solutions. For more information, visit www.ecardio.com.

PDF Print

Minneapolis and Houston – Preventice Solutions announced today that it will participate in the ACC.15, hosted by the American College of Cardiology on March 14-16, 2015 in San Diego, CA. Preventice Solutions will showcase its solutions for remote patient monitoring, education and engagement technologies.

The mobile healthcare horizon is bright with the offerings from Preventice Solutions. Simplifying the remote monitoring experience for patients and delivering the best continuity of care and a better seamless patient experience is precisely what Preventice Solutions vision is all about. It aims to deliver not only an unprecedented combination of cutting edge sensor technology but also best in class customer service.

Preventice Solutions is a strategic combination of: eCardio Diagnostics LLC, a leading provider of remote cardiac monitoring products and service and Preventice, an innovator in software solutions for remote patient care and developer of the PatientCare™ Platform and the BodyGuardian® Remote Monitoring Sensor. The two companies will now operate as wholly-owned subsidiaries of a newly formed holding company, Preventice Inc.

John H. Untereker, Executive Vice President and Chief Operating Officer, said “At Preventice Solutions, our collective focus is fixed on making a difference in the lives of those who rely on our innovations. We are constantly challenging ourselves to find novel solutions that improve patients’ wellbeing. Those outcomes are specially designed around deep insights uncovered from truly listening to our customers”.

“We are coming together at a pivotal time in the mobile healthcare industry. As health reform demands more focus on delivering quality outcomes and reducing costs, providers are turning to technology like remote monitoring to diagnose and treat more patients in ways that use time, money and human resources efficiently and effectively. Our shared vision is to become a worldwide leading remote monitoring company” said Jon Otterstatter, President and Chief Global Strategy Officer of Preventice Inc.

Preventice Solutions management team is committed to a pioneering collaboration to maintain agility while delivering the best scale and support to patients and healthcare providers.

Preventice Solutions booth: You can visit Preventice Solutions at Booth 2919.

PDF Print

Minneapolis and Houston – Preventice, developer of the PatientCare™ Platform and the BodyGuardian® Remote Monitoring Sensor and an innovator in software solutions for remote patient care, and eCardio Diagnostics LLC, a leading provider of remote cardiac monitoring products and services, announced today a strategic combination of Preventice and eCardio to drive innovation and growth in remote monitoring systems and mobile health applications. The two companies will now operate as wholly-owned subsidiaries of a newly formed holding company, Preventice, Inc.

The strategic combination strengthens eCardio’s ten-year history as a leader in remote cardiac monitoring with the addition of Preventice’s first-in-class, commercially available wireless remote cardiac monitoring system. It also provides Preventice with a national sales force and an award-winning monitoring center to allow for on-going market expansion of remote monitoring systems and mobile health applications.

Operating and corporate functions of the new holding company will be managed from eCardio’s corporate headquarters in Houston, while clinical research and product development activities will remain at Preventice’s Rochester, Minn., location. eCardio’s two Independent Diagnostic Testing Facilities will continue to monitor patients from Houston and South San Francisco.

Larry Lawson, founder and chief executive officer of eCardio, will serve as chairman and chief executive officer of the new holding company, Preventice, Inc. Jon Otterstatter, co-founder, president and chief executive officer of Preventice, has been appointed as president and global strategy officer of the holding company. eCardio’s chief operating officer, John Untereker, will serve as executive vice president and chief operating officer of the holding company.

“This strategic combination with Preventice will provide physicians with even greater access to products and services in the emerging market of cardiac remote patient care - one of the fastest growing segments in telehealth,” said Larry Lawson, the new chief executive officer of Preventice, Inc. “eCardio has focused on providing physician practices, academic medical centers and hospitals with the value-add tools they need to diagnose patients. In addition to mobile cardiac telemetry monitoring, streamlined reports via customized web portals, and successful EMR integrations, our customers can now look forward to a more robust and cost-effective offering.”

“We are excited about the opportunities that the combination with eCardio brings to accelerate, expand and leverage our shared values related to remote cardiac patient care,” said Jon Otterstatter, the new president and global strategy officer of Preventice, Inc. “The Merck Global Health Innovation Fund, LLC (GHIF), and Mayo Clinic have been exemplary partners. I am pleased that they will continue to partner with the new holding company.”

GHIF and Mayo Clinic were instrumental in the funding and development of Preventice’s BodyGuardian system. The Preventice-eCardio combination, of which GHIF is the primary stockholder, will continue to leverage the expertise of GHIF and the clinical insights of Mayo Clinic.

“Together, Preventice and eCardio create a strong and innovative player in the cardiac patient monitoring market, and provide differentiating opportunities to expand further in remote cardiac patient monitoring,” said Joseph Volpe, managing director of GHIF.

“These types of collaborations are how Mayo Clinic is extending its reach well beyond Rochester and we are pleased to see BodyGuardian take another step in its success story – invented by Mayo Clinic physicians, licensed and developed by Preventice, and now positioned to support patients globally,” said James Rogers, chair, Mayo Clinic Ventures.

About Preventice Solutions

Preventice Solutions, a leading developer of mobile health solutions and services, was created by a strategic combination of Preventice Services, formerly eCardio Diagnostics® and Preventice Technologies, formerly Preventice® in 2014.Together, we are designing the industry's superior customer service experience. Using insights to create revolutionary monitoring technologies and services that connect patients and caregivers, this tech-enabled, service-based approach can ultimately reduce the cost of care and improve health outcomes.  To learn more about Preventice Solutions, visit www.preventicesolutions.com

PDF Print

Minneapolis and Houston – Preventice, developer of the PatientCare™ Platform and the BodyGuardian® Remote Monitoring Sensor and an innovator in software solutions for remote patient care, and eCardio Diagnostics® LLC, a leading provider of remote cardiac monitoring products and services, announced today a strategic combination of Preventice and eCardio to drive innovation and growth in remote monitoring systems and mobile health applications. The two companies will now operate as wholly-owned subsidiaries of a newly formed holding company, Preventice, Inc.

The strategic combination strengthens eCardio’s ten-year history as a leader in remote cardiac monitoring with the addition of Preventice’s first-in-class, commercially available wireless remote cardiac monitoring system. It also provides Preventice with a national sales force and an award-winning monitoring center to allow for on-going market expansion of remote monitoring systems and mobile health applications.

Operating and corporate functions of the new holding company will be managed from eCardio’s corporate headquarters in Houston, while clinical research and product development activities will remain at Preventice’s Rochester, Minn., location. eCardio’s two Independent Diagnostic Testing Facilities will continue to monitor patients from Houston and South San Francisco.

Larry Lawson, founder and chief executive officer of eCardio, will serve as chairman and chief executive officer of the new holding company, Preventice, Inc. Jon Otterstatter, co-founder, president and chief executive officer of Preventice, has been appointed as president and global strategy officer of the holding company. eCardio’s chief operating officer, John Untereker, will serve as executive vice president and chief operating officer of the holding company.

“This strategic combination with Preventice will provide physicians with even greater access to products and services in the emerging market of cardiac remote patient care - one of the fastest growing segments in telehealth,” said Larry Lawson, the new chief executive officer of Preventice, Inc. “eCardio has focused on providing physician practices, academic medical centers and hospitals with the value-add tools they need to diagnose patients. In addition to mobile cardiac telemetry monitoring, streamlined reports via customized web portals, and successful EMR integrations, our customers can now look forward to a more robust and cost-effective offering.”

“We are excited about the opportunities that the combination with eCardio brings to accelerate, expand and leverage our shared values related to remote cardiac patient care,” said Jon Otterstatter, the new president and global strategy officer of Preventice, Inc. “The Merck Global Health Innovation Fund, LLC (GHIF), and Mayo Clinic have been exemplary partners. I am pleased that they will continue to partner with the new holding company.”

GHIF and Mayo Clinic were instrumental in the funding and development of Preventice’s BodyGuardian® system. The Preventice-eCardio combination, of which GHIF is the primary stockholder, will continue to leverage the expertise of GHIF and the clinical insights of Mayo Clinic.

“Together, Preventice and eCardio create a strong and innovative player in the cardiac patient monitoring market, and provide differentiating opportunities to expand further in remote cardiac patient monitoring,” said Joseph Volpe, managing director of GHIF.

“These types of collaborations are how Mayo Clinic is extending its reach well beyond Rochester and we are pleased to see BodyGuardian® take another step in its success story – invented by Mayo Clinic physicians, licensed and developed by Preventice, and now positioned to support patients globally,” said James Rogers, chair, Mayo Clinic Ventures.

PDF Print

HOUSTON, TX, February 4, 2014 — eCardio Diagnostics (www.ecardio.com), a leader in remote arrhythmia monitoring services, today announced the opening of its second Independent Diagnostic Testing Facility (IDTF) in San Francisco, California.

“This expansion, along with our continued employee and facility growth in Houston, will provide the resources for us to better serve our increasing patient population throughout the United States. We are excited about our growth opportunities in 2014 and beyond,” said eCardio’s Chairman and Chief Executive Officer, Larry Lawson.

Expanding to the West Coast is a strategic focus for eCardio as it continues to widen its reach and operations across the country. 

“The IDTF in San Francisco will enable us to better serve our practices and patients as well as to provide additional support to our Houston monitoring lab,” said eCardio’s President and Chief Operating Officer, John Untereker.

The new IDTF will further enhance eCardio’s strong presence in California and create a closer relationship with the burgeoning West Coast market. This impressive expansion is a testament to eCardio’s success and further emphasizes its commitment to providing excellent service to practices and patients nationwide.

eCardio has provided remote cardiac monitoring services since 2004, a decade of excellence and counting. For more information about eCardio, please visit  www.ecardio.com.

About eCardio 

Headquartered in Houston, Texas, eCardio Diagnostics, LLC is a leading partner in the delivery of optimal patient care by offering the complete wireless monitoring solution for physicians needing accurate and timely arrhythmia detection in the outpatient setting. Winner of numerous awards from the technology, health, and business sectors, eCardio provides a vast array of products including mobile cardiac telemetry (MCT), as well as looping and non-looping event monitors. The recently-introduced eCardio Verité monitor is a revolutionary single component, dual-mode device that utilizes advanced algorithms to auto-detect arrhythmias and transmit recordings in near, real time to innovative web platforms. Our leading-edge diagnostic innovations and digital solutions, combined with our award-winning Monitoring Center provide physicians and their patients with flexible, fast, and accurate arrhythmia monitoring solutions.

PDF Print